We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. The FDA approved its Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). In Jan 2017, Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs. In May 2017, the FDA also approved Kevzara for the same indication. In Jun 2017, the European Medicine Agency`s (EMA) also approved the drug for the same indication.
In this scenario, investor focus should remain on the performance of Eylea apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been mixed so far. In the last four reported quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 10.11%.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Currently, Regeneron has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s third-quarter 2017 earnings topped expectations. Our consensus called for EPS of $3.93 and the company reported EPS of $3.99.
Revenues: Revenues in the reported quarter also surpassed expectations. Regeneron posted revenues of $1.5 billion, compared to our consensus estimate of $1.46 billion.
Key Stats: Eylea net sales increased 12% year over year to $953 million in the United States. Regeneron expects Eylea net sales to grow approximately 10% in 2017 in the United States.
Check back later for our full write up on this REGN earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.Click for details >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Q3 Earnings Beat Estimates
Tarrytown, NY-based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. The FDA approved its Dupixent (dupilumab) Injection for the treatment of adults with moderate-to-severe atopic dermatitis (AD). In Jan 2017, Kevzara (sarilumab), an anti interleukin (IL)-6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs. In May 2017, the FDA also approved Kevzara for the same indication. In Jun 2017, the European Medicine Agency`s (EMA) also approved the drug for the same indication.
In this scenario, investor focus should remain on the performance of Eylea apart from the usual top-and bottom-line numbers.
Regeneron’s performance has been mixed so far. In the last four reported quarters, it surpassed earnings estimates on two occasions and missed in two. Overall, the company has recorded an average positive earnings surprise of 10.11%.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise | Regeneron Pharmaceuticals, Inc. Quote
Currently, Regeneron has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s third-quarter 2017 earnings topped expectations. Our consensus called for EPS of $3.93 and the company reported EPS of $3.99.
Revenues: Revenues in the reported quarter also surpassed expectations. Regeneron posted revenues of $1.5 billion, compared to our consensus estimate of $1.46 billion.
Key Stats: Eylea net sales increased 12% year over year to $953 million in the United States. Regeneron expects Eylea net sales to grow approximately 10% in 2017 in the United States.
Check back later for our full write up on this REGN earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.Click for details >>